Sophiris slides on prostate cancer data but vows to press on by Phil Taylor Tuesday, December 18, 2018 Sophiris will push its lead drug topsalysin into phase 3 testing, though a second dose showed no additional benefit in its prostate cancer trial.
Sophiris clears its lead drug following patient death in study by Conor Hale Thursday, August 30, 2018 Sophiris Bio found that it was unlikely its lead prostate cancer drug caused a patient’s death, which halted dosing in a study two months ago.
Sophiris cuts second dose in topsalysin trial after patient dies by Conor Hale Monday, June 25, 2018 Sophiris halted additional doses of topsalysin in a prostate cancer study after the death of a patient on the same day he received a second dose.
